Melanoma-associated antigen C2
Melanoma-associated antigen C2 (43-57) is a synthetic peptide fragment derived from the MAGE-C2 protein, an established member of the melanoma antigen gene family. This peptide encompasses amino acids 43 to 57 of the parent protein, a region known for its immunological relevance and frequent investigation in tumor immunology. Due to its sequence specificity and well-characterized origin, the peptide is widely utilized as a research tool in studies focused on antigen processing, immune recognition, and the molecular mechanisms underlying tumor-specific antigenicity. Its defined structure and functional context make it especially valuable for dissecting T-cell responses and antigen presentation dynamics in cancer research and related fields.
Epitope mapping: Researchers employ this peptide fragment to precisely delineate T-cell epitopes within the MAGE-C2 protein. By exposing immune cells to the defined sequence, investigators can identify and characterize the specific regions recognized by cytotoxic T lymphocytes, thereby enhancing understanding of the antigenic determinants that drive cellular immune responses against tumor-associated antigens. Such studies are critical for elucidating the mechanisms of immune surveillance and for informing the rational design of immunotherapeutic strategies targeting cancer-specific epitopes.
Immunogenicity assessment: The 43-57 peptide is frequently used to evaluate the immunogenic potential of MAGE-C2-derived sequences in both in vitro and ex vivo systems. Its application enables the measurement of cytokine release, proliferation, and cytolytic activity of T cells upon antigen exposure. These assays provide valuable insights into the capacity of the peptide to stimulate immune effector functions, supporting investigations into tumor immunity and the identification of candidates for further immunological development.
Antigen presentation studies: As a defined peptide, the fragment serves as an essential tool for probing the mechanisms of major histocompatibility complex (MHC) class I and II peptide loading and presentation. By incorporating the sequence into antigen-presenting cell assays, researchers can assess peptide binding affinity, stability, and cross-presentation efficiency. Such studies contribute to a deeper understanding of how tumor antigens are processed and displayed to the immune system, informing the development of more effective antigen delivery platforms and immunomodulatory approaches.
Peptide-based assay development: The sequence is increasingly utilized in the design and optimization of immunological assays such as ELISPOT, flow cytometry-based tetramer staining, and enzyme-linked immunosorbent assays (ELISAs). These applications facilitate the sensitive detection and quantification of antigen-specific T cell populations, enabling robust monitoring of immune responses in preclinical research and experimental immunology. The use of a well-characterized synthetic peptide ensures assay specificity and reproducibility, which are essential for generating reliable and interpretable data.
Structural and binding studies: The Melanoma-associated antigen C2 (43-57) fragment is also employed in biophysical and structural investigations aimed at elucidating peptide-MHC and peptide-T cell receptor (TCR) interactions. By incorporating the peptide into crystallography, NMR, or surface plasmon resonance experiments, scientists can analyze the molecular details of antigen recognition and binding. These insights are fundamental for advancing the structural immunology of cancer antigens and for guiding the rational design of next-generation immunotherapeutic agents and diagnostic reagents.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More